Browsing: Novo

Novo Nordisk said on Friday it is ​seeking a preliminary U.S. ​court injunction to immediately block ​obesity and diabetes drug advertisements by Eli Lilly

Novo Nordisk said it is asking a U.S. court to preliminarily halt rival Eli Lilly from advertising weight-loss drugs, days after accusing the Indianapolis drugmaker of using deceptive ads to mislead consumers in a lawsuit

Danish pharmaceutical company Novo Nordisk (NVO, Financials), a maker of diabetes and obesity therapies, wants a U.S. court to issue a preliminary injunction to halt rival Eli Lilly’s advertising.Novo accused Lilly of violating false advertising and unfair competition rules with its Zepbound and Mounjaro campaigns for obesity and diabetes treatment respectively.Lilly said Novo compared the…

COPENHAGEN, July 24 (Reuters) – Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately ‌block obesity and diabetes drug advertisements by Eli Lilly, in ‌a further escalation of the rivalry between the two groups

COPENHAGEN, July 24 (Reuters) – Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly, in a further escalation of the rivalry between the two groups

This is a paid press release. Contact the press release distributor directly with any inquiries.

JAKARTA – Every child has the right to grow healthy and achieve the best future. On the momentum of this year’s National Children’s Day, the joint commitment to strengthen children’s health is becoming increasingly important, especially in the midst of increasing prevalence of obesity and the need for optimal access to treatment for children with…

Two pharmaceutical giants that dominate the global obesity drug market have clashed over advertising for their obesity treatments. Analysts say the fight to seize control of the rapidly growing obesity drug market, now worth hundreds of billions of dollars, has intensified. 

Novo Nordisk stock is trading close to recent record levels, reflecting sustained investor confidence in the Danish pharmaceutical group (ISIN DK0062498333) as demand for its obesity and diabetes drugs continues to reshape earnings and market expectations

Two of the world’s biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, accusing the U.S. drugmaker of false advertising